NasdaqCM:VRML

Stock Analysis Report

Executive Summary

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Risks

  • Vermillion has significant price volatility in the past 3 months.
  • Vermillion is not covered by any analysts.

Similar Companies

Share Price & News

How has Vermillion's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-14.1%

VRML

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

-19.1%

VRML

9.7%

US Medical Equipment

0.7%

US Market

VRML underperformed the Medical Equipment industry which returned 9.9% over the past year.

VRML underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

VRMLIndustryMarket
7 Day-14.1%1.2%-0.6%
30 Day1.9%3.5%4.9%
90 Day-37.5%3.2%1.7%
1 Year-19.1%-19.1%10.6%9.7%3.0%0.7%
3 Year-59.6%-59.6%70.6%65.4%44.8%35.4%
5 Year-69.9%-69.9%139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Vermillion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

Did Vermillion, Inc. (NASDAQ:VRML) Insiders Buy Up More Shares?

Valuation

Is Vermillion undervalued based on future cash flows and its price relative to the stock market?

3.88x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Vermillion to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Vermillion to establish if it is available at substantial discount.


Price Based on Earnings

Vermillion is loss making, we can't compare its value to the US Medical Equipment industry average.

Vermillion is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Vermillion, we can't assess if its growth is good value.


Price Based on Value of Assets

Vermillion is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Vermillion expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vermillion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vermillion performed over the past 5 years?

10.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Vermillion does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Vermillion's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Vermillion's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Vermillion has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Vermillion has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Vermillion improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Vermillion's financial position?


Financial Position Analysis

Vermillion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Vermillion's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Vermillion's level of debt (10.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (6.3% vs 10.4% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 12.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Vermillion has sufficient cash runway for 1.4 years based on current free cash flow.

Vermillion has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -23.1% each year.


Next Steps

Dividend

What is Vermillion's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Vermillion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Vermillion's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Vermillion has not reported any payouts.

Unable to verify if Vermillion's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Vermillion has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Vermillion's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Valerie Palmieri (58yo)

4.7yrs

Tenure

US$684,457

Compensation

Ms. Valerie Barber Palmieri has been the Chief Executive Officer and President at Vermillion, Inc. since January 1, 2015. Ms. Palmieri served as the Chief Operating Officer of Vermillion, Inc. since joined ...


CEO Compensation Analysis

Valerie's remuneration is higher than average for companies of similar size in United States of America.

Valerie's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.8yrs

Average Tenure

The average tenure for the Vermillion management team is less than 2 years, this suggests a new team.


Board Age and Tenure

5.3yrs

Average Tenure

61yo

Average Age

The tenure for the Vermillion board of directors is about average.


Insider Trading

More shares have been bought than sold by Vermillion individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$4,000,00002 Jul 19
Jack Schuler
EntityIndividual
Shares5,000,000
Max PriceUS$0.80
BuyUS$3,600,00002 Jul 19
Henri Schuler
EntityIndividual
Shares4,500,000
Max PriceUS$0.80
BuyUS$30,00001 Jul 19
Valerie Palmieri
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares37,500
Max PriceUS$0.80
BuyUS$6,29217 May 19
Robert Beechey
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,000
Max PriceUS$1.26
BuyUS$14,25006 Dec 18
Robert Beechey
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares25,000
Max PriceUS$0.57

Ownership Breakdown


Management Team

  • Valerie Palmieri (58yo)

    CEO, President & Director

    • Tenure: 4.7yrs
    • Compensation: US$684.46k
  • Bob Beechey (56yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
    • Compensation: US$395.73k
  • Chris Goulart

    Senior Vice President of Commercial Operations

    • Tenure: 1.3yrs

Board Members

  • David Schreiber (59yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$99.00k
  • Valerie Palmieri (58yo)

    CEO, President & Director

    • Tenure: 4.7yrs
    • Compensation: US$684.46k
  • Jim Burns (72yo)

    Director

    • Tenure: 14.3yrs
    • Compensation: US$92.00k
  • Jim LaFrance (60yo)

    Chairman

    • Tenure: 5.8yrs
    • Compensation: US$121.25k
  • Dan Chan

    Member of Scientific Advisory Board

    • Tenure: 13.3yrs
  • Veronica Geraldine Jordan (68yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$99.50k
  • Donald Munroe (62yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$484.75k
  • Judith Wolf

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Robert Bristow

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Calaneet Balas

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Vermillion, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vermillion, Inc.
  • Ticker: VRML
  • Exchange: NasdaqCM
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$53.455m
  • Shares outstanding: 97.19m
  • Website: https://www.vermillion.com

Number of Employees


Location

  • Vermillion, Inc.
  • Building III
  • Suite 100
  • Austin
  • Texas
  • 78738
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CUL1DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2000
VRMLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2000

Biography

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health out ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:02
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.